Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 158-164

  Navin, Thomas R ^a,c   Rimland, David ^a   Lennox, Jeffrey L ^a   Jernigan, John ^a   Cetron, Marty ^a,b   Hightower, Allen ^a   Roberts, Jacqueline M ^a   Kaplan, Jonathan E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENCE RISK;

ADULT; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PNEUMONIA; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0033966982     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315196     Document Type: Article

References (43)

1. 1. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying from human immunodeficiency virus infection, United States, 1987-1992, Ann Intern Med 1995; 123:933-6.
2. 2. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333:845-51.
3. 3. Caiaffa WT, Vlahov D, Graham NMH, et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injecting drug users. Am J Respir Crit Care Med 1994; 150:1493-8.
4. 4. Teira R, Virosta M, Zubero Z, et al. Neumonías bacterianas como marcador de riesgo de nuevas enfermedades bacterianas en pacientes infectados por el HIV. Inferm Infec Microbiol Clin 1996; 14:361-6.
5. 5. Caiaffa WT, Graham NMH, Vlahov D. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol 1993; 138:909-22.
6. 6. Burns DN, Hillman D, Neaton JD, et al. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:374-83.
7. 7. Finkelstein DM, Williams PL, Molenberghs G, et al. Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:38-45.
8. 8. Galai N, Park LP, Wesch J, Visscher B, Riddler S, Margolick JB. Effect of smoking on the clinical progression of HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:451-8.
9. 9. Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A, and the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322:161-5.
10. 10. Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA 1995; 273:1197-1202.
11. 11. Lidman C, Berglund O, Tynell E, Lindback S. CD4+ cells and CD4+ percent as risk markers for Pneumocystis carinii pneumonia (PCP): implications for primary PCP prophylaxis. Scand J Infect Dis 1992; 24:157-60.
12. 12. Goedert JJ. The risk of Pneumocystis carinii pneumonia. N Engl J Med 1990; 322:1607.
13. 13. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. Clin Infect Dis 1995; 21:106-13.
14. 14. Muñoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1991. Am J Epidemiol 1993; 137:423-38.
15. 15. Chan ISF, Neaton JD, Saravolatz LD, Crane LR, Osterberger J, and the Community Programs for Clinical Research on AIDS. Frequencies of opportunistic diseases prior to death among HIV-infected persons. AIDS 1995; 9:1145-51.
16. 16. Boschini A, Smacchia C, Fine MD, et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996; 23:107-13.
17. 17. Jensen BN, Gerstoft J, Skinhoj P. The prognosis in HIV-infected patients with pneumonia: relation to microbiological diagnosis. Dan Med Bull 1991; 38:468-70.
18. 18. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven Publishers, 1998:147-62.
19. 19. SAS statistical software, volume 6.12. Cary, NC: SAS Institute, 1998.
20. 20. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185-9.
21. 21. Leoung GS, Feigal DW, Montgomery AV, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. N Engl J Med 1990; 323:769-75.
22. 22. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992; 6:1169-74.
23. 23. Schneider MME, Hoepelman AIM, Schattenkek JKME, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1836-41.
24. 24. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. N Engl J Med 1992; 327:1842-8.
25. 25. Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993; 328:1514-20.
26. 26. Mallolas J, Zamora L, Gatell JM, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993; 7: 59-64.
27. 27. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995; 20:531-41.
28. 28. Bozzette SA, Finkelstein D, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:693-9.
29. 29. Bucher HC, Griffith L. Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:104-14.
30. 30. Warnock AC, Rimland D. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocytis carinii pneumonia. Pharmacotherapy 1996; 16:1030-8.
31. 31. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:177-88.
32. 32. Nielson TL, Jensen BN, Nelsing S, Mathiesen LR, Skinhoj P, Nielsen JO. Randomized study of sulfamethoxale-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Scand J Infect Dis 1995; 27:217-20.
33. 33. Wallace JM, Rao AV, Glassroth J, et al. Respiratory illness in persons with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1523-9.
34. 34. Wallace JM, Hansen NI, LaVange L, et al. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Am J Respir Crit Care Med 1997; 155:72-80.
35. 35. Jones JL, Hanson DL, Chu SY, et al. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. AIDS 1996; 10:1393-9.
36. 36. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in HIV-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126-32.
37. 37. Chu SY, Hanson DL, Ciesielski C, Ward JW. Prophylaxis against Pneumocystis carinii pneumonia at higher CD4+ T-cell counts. JAMA 1995; 273: 848.
38. 38. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be member of the fungi. Nature 1988; 334:519-22.
39. 39. Stringer SL, Stringer JR, Blase MA, Walser PD, Cushion MT. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp Parasitol 1989; 68:450-61.
40. 40. Bartlett MS, Queener SF, Shaw MM, Richardson JD, Smith JW. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob Agents Chemother 1994; 38:1859-61.
41. 41. Walzer PD. Pneumocystis carinii new clinical spectrum? N Engl J Med 1991; 324:263-5.
42. 42. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus (suppl). MMWR Recommendations and Reports 1999; 48(RR-10):1-66.
43. 43. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol 1997; 35:2745-7.